Kristian Humer serves as Chief Financial Officer at 4D Molecular Therapeutics Inc. (4DMT), a clinical-stage gene therapy company pioneering targeted genetic medicines for large prevalent diseases such as those in ophthalmology, cardiology, and pulmonology. Appointed CFO in September 2021, Humer leads the company's financial strategy, including capital raising, investor relations, financial planning and analysis, and reporting. Under his leadership, 4DMT has advanced its pipeline, including key programs like 4D-150 for wet AMD and diabetic macular edema, while navigating the complexities of biotech financing in a dynamic market. Prior to joining 4DMT, Humer was CFO at Aduro Biotech from 2018 to 2021, where he managed financial operations during a period of strategic restructuring and partnership development. Before that, he served as Senior Vice President of Finance at Relypsa, Inc., contributing to its successful initial public offering in 2014 and subsequent $1.3 billion acquisition by Galapagos NV in 2016. Earlier in his career, Humer held roles as Vice President of Finance at Amyris, Inc., and began his professional journey at Deloitte, where he specialized in audit and advisory services for life sciences and technology clients. Humer's achievements include orchestrating multiple financing rounds totaling hundreds of millions for innovative biotech firms, optimizing capital structures to fuel R&D, and fostering strong relationships with institutional investors. A certified public accountant with an MBA from the University of California, Berkeley, Haas School of Business, and a BS in Business Administration from the University of Southern California, Humer brings over two decades of experience to 4DMT, positioning the company for sustained growth and potential breakthroughs in genetic medicine.